Literature DB >> 19363254

Effects of 4-hydroxy-nonenal and Amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells.

Rui Wang1, Suqing Wang, James S Malter, Deng-Shun Wang.   

Abstract

The cerebral accumulation of amyloid-beta (Abeta) is a consistent feature of and likely contributor to the development of Alzheimer's disease (AD). In addition to dysregulated production, increasing experimental evidence suggests reduced catabolism plays an important role in Abeta accumulation. Although endothelin converting enzyme (ECE) and insulin degrading enzyme (IDE) degrade and thus contribute to regulating the steady-state levels of Abeta, how these enzymes are regulated remain poorly understood. In this study, we investigated the effects of 4-hydroxy-nonenal (HNE) and Abeta on the expression and activity of ECE-1 and IDE in human neuroblastoma SH-SY5Y cells. Treatment with HNE or Abeta upregulated ECE-1 mRNA and protein, while IDE was unchanged. Although both ECE-1 and IDE were oxidized within 24 h of HNE or Abeta treatment, ECE-1 catalytic activity was elevated while IDE specific activity was unchanged. The results demonstrated for the first time that both ECE-1 and IDE are substrates of HNE modification induced by Abeta. In addition, the results suggest complex mechanisms underlying the regulation of their enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363254      PMCID: PMC2819406          DOI: 10.3233/JAD-2009-1066

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  77 in total

Review 1.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide.

Authors:  D A Butterfield; J Drake; C Pocernich; A Castegna
Journal:  Trends Mol Med       Date:  2001-12       Impact factor: 11.951

2.  4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease.

Authors:  L M Sayre; D A Zelasko; P L Harris; G Perry; R G Salomon; M A Smith
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

3.  Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain.

Authors:  K Yasojima; E G McGeer; P L McGeer
Journal:  Brain Res       Date:  2001-11-16       Impact factor: 3.252

Review 4.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.

Authors:  D Allan Butterfield; Christopher M Lauderback
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

5.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

6.  Exacerbation of apoptosis of cortical neurons following traumatic brain injury in par-4 transgenic mice.

Authors:  Daniel J Payette; Jun Xie; Najeeb Shirwany; Qing Guo
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 7.  Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.

Authors:  Mark S Forman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Med       Date:  2004-10       Impact factor: 53.440

8.  Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease.

Authors:  B Funalot; T Ouimet; A Claperon; C Fallet; A Delacourte; J Epelbaum; T Subkowski; N Léonard; V Codron; J-P David; P Amouyel; J-C Schwartz; N Helbecque
Journal:  Mol Psychiatry       Date:  2004-12       Impact factor: 15.992

Review 9.  Radical AGEing in Alzheimer's disease.

Authors:  M A Smith; L M Sayre; V M Monnier; G Perry
Journal:  Trends Neurosci       Date:  1995-04       Impact factor: 13.837

Review 10.  Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress.

Authors:  Laura Canevari; Andrey Y Abramov; Michael R Duchen
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

View more
  5 in total

1.  Dynamic alteration of neprilysin and endothelin-converting enzyme in age-dependent APPswe/PS1dE9 mouse model of Alzheimer's disease.

Authors:  Li Zhou; Jianxu Liu; Dong Dong; Chunsheng Wei; Rui Wang
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

2.  Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.

Authors:  Suqing Wang; Rui Wang; Lang Chen; David A Bennett; Dennis W Dickson; Deng-Shun Wang
Journal:  J Neurochem       Date:  2010-07-30       Impact factor: 5.372

3.  Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer's Disease.

Authors:  Ali Aijaz Hussain; Yunhee Lee; Jin-Jun Zhang; Paul T Francis; John Marshall
Journal:  J Neurodegener Dis       Date:  2017-01-18

Review 4.  Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease.

Authors:  Sang-Sun Yoon; Sangmee Ahn Jo
Journal:  Biomol Ther (Seoul)       Date:  2012-05       Impact factor: 4.634

Review 5.  Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.

Authors:  J Scott Miners; Jennifer C Palmer; Hannah Tayler; Laura E Palmer; Emma Ashby; Patrick G Kehoe; Seth Love
Journal:  Front Aging Neurosci       Date:  2014-09-11       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.